Kelyniam Global Releases Q3 Financials, Strong Performance Continues
Kelyniam Global (KLYG) reported strong Q3 2024 financial results, with total revenue reaching $2,492,607, a 43% increase from the previous year. The company's gross margin grew 44% to $1,956,714, while operating profit improved significantly to $273,248 from a loss of ($329,993). EBITDA also turned positive at $349,099 compared to previous year's loss.
The company attributes its success to overnight service, quality focus, new surgeon acquisitions, and effective expense management. Notable developments include increased market acceptance of CustomizedBone™ regenerative implant and NEOS Cranial Loop fixation products.
Kelyniam Global (KLYG) ha riportato risultati finanziari solidi per il terzo trimestre del 2024, con un fatturato totale di 2.492.607 dollari, un aumento del 43% rispetto all'anno precedente. Il margine lordo dell'azienda è cresciuto del 44% fino a 1.956.714 dollari, mentre l'utile operativo è migliorato significativamente a 273.248 dollari rispetto a una perdita di -329.993 dollari. L'EBITDA è diventato positivo a 349.099 dollari rispetto alla perdita dell'anno precedente.
L'azienda attribuisce il suo successo al servizio notturno, alla focalizzazione sulla qualità, alle nuove acquisizioni di chirurghi e alla gestione efficace delle spese. Sviluppi notevoli includono una maggiore accettazione del mercato per il dispositivo impiantabile rigenerativo CustomizedBone™ e i prodotti per la fissazione NEOS Cranial Loop.
Kelyniam Global (KLYG) reportó resultados financieros sólidos en el tercer trimestre de 2024, con ingresos totales que alcanzaron 2,492,607 dólares, un aumento del 43% con respecto al año anterior. El margen bruto de la compañía creció un 44% hasta 1,956,714 dólares, mientras que el beneficio operativo mejoró significativamente a 273,248 dólares desde una pérdida de -329,993 dólares. El EBITDA también se volvió positivo con 349,099 dólares en comparación con la pérdida del año anterior.
La compañía atribuye su éxito al servicio nocturno, el enfoque en la calidad, la adquisición de nuevos cirujanos y una gestión efectiva de gastos. Los desarrollos notables incluyen una mayor aceptación en el mercado del implante regenerativo CustomizedBone™ y los productos de fijación NEOS Cranial Loop.
Kelyniam Global (KLYG)는 2024년 3분기 재무 결과가 좋다고 보고했으며, 총 수익이 2,492,607달러에 달하여 지난해 대비 43% 증가했습니다. 회사의 총 이익률은 44% 증가하여 1,956,714달러에 달했고, 운영 이익은 273,248달러로 크게 개선되었으며, 이전의 손실 -329,993달러에서 회복되었습니다. EBITDA도 지난해의 손실에 비해 349,099달러로 긍정적인 전환을 보였습니다.
회사는 성공의 원인을 야간 서비스, 품질 초점, 새로운 외과 의사 확보 및 효과적인 비용 관리에 두고 있습니다. 주목할 만한 발전으로는 CustomizedBone™ 재생 이식편과 NEOS Cranial Loop 고정 제품에 대한 시장 수용의 증가가 있습니다.
Kelyniam Global (KLYG) a signalé de solides résultats financiers pour le troisième trimestre de 2024, avec un chiffre d'affaires total atteignant 2.492.607 dollars, soit une augmentation de 43% par rapport à l'année précédente. La marge brute de l'entreprise a augmenté de 44% pour atteindre 1.956.714 dollars, tandis que le bénéfice d'exploitation s'est considérablement amélioré à 273.248 dollars, contre une perte de -329.993 dollars. L'EBITDA est également devenu positif à 349.099 dollars par rapport à la perte de l'année précédente.
L'entreprise attribue son succès à son service de nuit, à son attention à la qualité, à l'acquisition de nouveaux chirurgiens et à une gestion efficace des dépenses. Les développements notables comprennent une acceptation accrue sur le marché de l'implant régénératif CustomizedBone™ et des produits de fixation NEOS Cranial Loop.
Kelyniam Global (KLYG) hat starke Finanzzahlen für das dritte Quartal 2024 gemeldet, mit einem Gesamterlös von 2.492.607 Dollar, was einem Anstieg von 43% im Vergleich zum Vorjahr entspricht. Die Bruttomarge des Unternehmens wuchs um 44% auf 1.956.714 Dollar, während der operative Gewinn von einem Verlust von -329.993 Dollar auf 273.248 Dollar erheblich anstieg. Das EBITDA wurde ebenfalls positiv und belief sich auf 349.099 Dollar im Vergleich zum Verlust des Vorjahres.
Das Unternehmen führt seinen Erfolg auf den nächtlichen Service, die Qualitätsfokussierung, die Akquisition neuer Chirurgen und ein effektives Kostenmanagement zurück. Bemerkenswerte Entwicklungen umfassen eine erhöhte Marktakzeptanz für das regenerative Implantat CustomizedBone™ und die NEOS Cranial Loop Fixationsprodukte.
- Revenue increased 43% year-over-year to $2.49M
- Gross margin improved 44% to $1.96M
- Operating profit turned positive at $273K from previous loss
- EBITDA improved to $349K from previous year's loss
- Expanded customer base with new surgeons and hospitals
- Ongoing pricing pressures in the market
"Kelyniam has consistently delivered strong performance year on year," said Ross Bjella, CEO of Kelyniam. "Our unwavering focus on overnight service and quality has been reflected in our third-quarter results."
Financial Highlights (Nine months ended September 30, 2024, vs. September 30, 2023)
- Total Revenue:
$2,492,607 43% from$1,741,587 - Gross Margin:
$1,956,714 44% from$1,349,684 - Operating Profit:
$273,248 $329,993 $603,241 - EBITDA:
$349,099 $254,726 $603,825
"We are proud of our profitable growth in 2024," said Bjella. "Our team has been invigorated by rising sales, the addition of new surgeons and hospital customers, and a stringent focus on expense management. These results support Kelyniam's capability to generate cash and capitalize on our operating model's leverage. While pricing pressures persist, strategic growth and diligent expense management have driven the significant turnaround in our operating profit."
Other events occurring in the third quarter included:
- Greater market acceptance for the CustomizedBoneÔ (hydroxyapatite) regenerative implant
- Greater trial and usage of the NEOS Cranial Loop fixation
- Attendance at the College of Neurological Surgeons annual meeting
Kelyniam Inc., specializes in the rapid production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers. The Company develops, manufactures, and distributes custom cranial and maxillo-facial implants for patients. Kelyniam works directly with surgeons, health systems and payors to improve clinical and cost-of-care outcomes. Kelyniam's web site address is www.Kelyniam.com.
As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; the Company's ability to execute its service and product sales plans; changes in the status of ability to market products; and the risks described from time to time in the Company's SEC reports. Contact: Terrance Kurtenbach, Chief Financial Officer, Kelyniam Inc. (800) 280-8192
View original content:https://www.prnewswire.com/news-releases/kelyniam-global-releases-q3-financials-strong-performance-continues-302300319.html
SOURCE Kelyniam Global Inc
FAQ
What was Kelyniam Global's (KLYG) revenue growth in Q3 2024?
How much did KLYG's operating profit improve in Q3 2024?
What were the key products driving Kelyniam's (KLYG) growth in Q3 2024?
